Right ventricular failure is a challenging syndrome with a complex pathophysiology and it is burdened by high mortality rate. Diagnosis of right ventricular failure remains difficult with pharmacological strategies being limited. Mechanical circulatory support (MCS) which has been introduced into clinical practice, is an important strategy to rapidly stabilize patients. However, all treatment strategies have a low level of evidence mainly related to the paucity of data.
The aim of the current Research Topic is to propose and discuss current management strategies, ongoing research findings, and future perspectives in the diagnosis and treatment of right ventricular failure. Led by an expert team of specialists, the Research Topic will accept manuscripts within this area of research - with the aim of giving the reader an overview of the latest discoveries and new findings, analysis of previously published data, new opinions and perspectives, and methods and protocols (when relevant). For that reason, all article types accepted by Frontiers are encouraged.
Sub-themes for this topic may include, but are not limited to:
1) Invasive and non-invasive tools and parameters to diagnose and monitor the right ventricular function.
2) Recent advances in RV failure pathophysiology and their application in clinical practice.
3) Pharmacological and mechanical circulatory support treatment strategies and proposed management algorithm
Conflict of Interest Statement:
Dr. Roberto Lorusso - Member of the medical advisory board of Eurosets and Resenius. Consultant for Medtronic, LivaNova, Getinge, Abiomed and CORCYM. Received a research grants from Medtronic
Dr. Navin Kapur receives consulting/speaker honoraria and institutional grants support from: Abbott Laboratories, Abiomed Inc, Boston Scientific, Edwards, Medtronic, Getinge, LivNova, MDStart, Precardia and Zoll.
Right ventricular failure is a challenging syndrome with a complex pathophysiology and it is burdened by high mortality rate. Diagnosis of right ventricular failure remains difficult with pharmacological strategies being limited. Mechanical circulatory support (MCS) which has been introduced into clinical practice, is an important strategy to rapidly stabilize patients. However, all treatment strategies have a low level of evidence mainly related to the paucity of data.
The aim of the current Research Topic is to propose and discuss current management strategies, ongoing research findings, and future perspectives in the diagnosis and treatment of right ventricular failure. Led by an expert team of specialists, the Research Topic will accept manuscripts within this area of research - with the aim of giving the reader an overview of the latest discoveries and new findings, analysis of previously published data, new opinions and perspectives, and methods and protocols (when relevant). For that reason, all article types accepted by Frontiers are encouraged.
Sub-themes for this topic may include, but are not limited to:
1) Invasive and non-invasive tools and parameters to diagnose and monitor the right ventricular function.
2) Recent advances in RV failure pathophysiology and their application in clinical practice.
3) Pharmacological and mechanical circulatory support treatment strategies and proposed management algorithm
Conflict of Interest Statement:
Dr. Roberto Lorusso - Member of the medical advisory board of Eurosets and Resenius. Consultant for Medtronic, LivaNova, Getinge, Abiomed and CORCYM. Received a research grants from Medtronic
Dr. Navin Kapur receives consulting/speaker honoraria and institutional grants support from: Abbott Laboratories, Abiomed Inc, Boston Scientific, Edwards, Medtronic, Getinge, LivNova, MDStart, Precardia and Zoll.